Apnimed (APMD) vs Kura Oncology (KURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Apnimed is the larger company by market cap ($669.8 million vs $634.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APMD | KURA |
|---|---|---|
| Share price | $16.09 | $6.91 |
| Market cap | $669.84M | $634.88M |
| 1-day change | -6.70% | -5.99% |
| YTD return | — | -33.49% |
| 1-year return | — | -38.14% |
| 5-year return | — | -50.66% |
| P/E ratio (TTM) | 1.21 | — |
| EPS (TTM) | $13.34 | $-3.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $67.48M |
| Revenue growth (YoY) | — | +25.24% |
| Net income (latest FY) | — | $-278.67M |
| Operating margin | — | -449.94% |
| Net margin | — | -412.95% |
| 52-week high | $35.29 | $13.90 |
| 52-week low | $13.88 | $6.75 |
| Distance from 52-week high | -54.41% | -50.29% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +210.75% | +357.60% |
| Average volume | 458.58K | 2.10M |
| Shares outstanding | 41.63M | 91.88M |
| Employees | 112 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Apnimed
APMD stock →Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
APMD vs KURA FAQ
Which is bigger, Apnimed or Kura Oncology?
Apnimed (APMD) is larger, with a market capitalization of $669.84M compared with $634.88M for Kura Oncology (KURA).
Are Apnimed and Kura Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.